Karaağaç M - Search Results

1

The XRCC1 and TP53 gene polymorphisms are associated with advanced-stage disease and early distant metastasis at diagnosis in non-small cell lung cancer.

Karaağaç M, Geredeli Ç, Yıldırım MS, Altınok T, Dede İ, İnal A, Zamani AG, Kaya B, Demirkazık A, Artaç M. Karaağaç M, et al. J Cancer Res Ther. 2023 Jul-Sep;19(5):1248-1254. doi: 10.4103/jcrt.jcrt_1657_21. J Cancer Res Ther. 2023. PMID: 37787291 Free article.

2

Do high-risk features support the use of adjuvant chemotherapy in stage II colon cancer? A Turkish Oncology Group study.

Artac M, Turhal NS, Kocer M, Karabulut B, Bozcuk H, Yalcin S, Karaagac M, Gündüz S, Isik N, Uygun K. Artac M, et al. Among authors: karaagac m. Tumori. 2014 Mar-Apr;100(2):143-8. doi: 10.1177/030089161410000205. Tumori. 2014. PMID: 24852857

3

Prognostic value of ERCC1, ERCC2, XRCC1, and TP53 single nucleotide polymorphisms in patients with early-stage non-small cell lung cancer.

Geredeli C, Artac M, Yildirim S, Inal A, Dede I, Guler T, Boruban MC, Koral L, Karaagac M, Zamani AG, Altinok T, Aribas O, Bozcuk H, Demirkazik A. Geredeli C, et al. Among authors: karaagac m. Tumour Biol. 2015 Jun;36(6):4279-85. doi: 10.1007/s13277-015-3066-2. Epub 2015 Jan 18. Tumour Biol. 2015. PMID: 25596702

4

Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study.

Artaç M, Coşkun HŞ, Dane F, Karabulut B, Korkmaz L, Karaağaç M, Çabuk D, Karabulut S, Faruk Aykan N, Doruk H, Avcı N, Turhal NS. Artaç M, et al. Among authors: karaagac m. J Gastrointest Cancer. 2016 Sep;47(3):264-72. doi: 10.1007/s12029-016-9823-7. J Gastrointest Cancer. 2016. PMID: 27126591

5

Primary Tumor Resection and Survival in Patients with Stage IV Gastric Cancer.

Müsri FY, Mutlu H, Karaağaç M, Eryilmaz MK, Gündüz Ş, Artaç M. Müsri FY, et al. Among authors: karaagac m. J Gastric Cancer. 2016 Jun;16(2):78-84. doi: 10.5230/jgc.2016.16.2.78. Epub 2016 Jun 24. J Gastric Cancer. 2016. PMID: 27433392 Free PMC article.

6

Prognostic Impact of Neutrophil/Lymphocyte Ratio, Platelet Count, CRP, and Albumin Levels in Metastatic Colorectal Cancer Patients Treated with FOLFIRI-Bevacizumab.

Artaç M, Uysal M, Karaağaç M, Korkmaz L, Er Z, Güler T, Börüban MC, Bozcuk H. Artaç M, et al. Among authors: karaagac m. J Gastrointest Cancer. 2017 Jun;48(2):176-180. doi: 10.1007/s12029-016-9879-4. J Gastrointest Cancer. 2017. PMID: 27714653

7

Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients.

Artaç M, Korkmaz L, Coşkun HŞ, Dane F, Karabulut B, Karaağaç M, Çabuk D, Karabulut S, Aykan NF, Doruk H, Avcı N, Turhal NS. Artaç M, et al. Among authors: karaagac m. J Gastrointest Cancer. 2019 Jun;50(2):214-220. doi: 10.1007/s12029-017-0047-2. J Gastrointest Cancer. 2019. PMID: 29302856

8

Kras-mutation influences outcomes for palliative primary tumor resection in advanced colorectal cancer-a Turkish Oncology Group study.

Korkmaz L, Coşkun HŞ, Dane F, Karabulut B, Karaağaç M, Çabuk D, Karabulut S, Aykan NF, Doruk H, Avcı N, Turhal NS, Artaç M. Korkmaz L, et al. Among authors: karaagac m. Surg Oncol. 2018 Sep;27(3):485-489. doi: 10.1016/j.suronc.2018.05.032. Epub 2018 May 30. Surg Oncol. 2018. PMID: 30217306

9

Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes.

Esin E, Oksuzoglu B, Bilici A, Cicin I, Kostek O, Kaplan MA, Aksoy S, Aktas BY, Ozdemir O, Alacacioglu A, Cabuk D, Sumbul AT, Sakin A, Paydas S, Yetisir E, Er O, Korkmaz T, Yildirim N, Sakalar T, Demir H, Artac M, Karaagac M, Harputluoglu H, Bilen E, Erdur E, Degirmencioglu S, Aliyev A, Cil T, Olgun P, Basaran G, Gumusay O, Demir A, Tanrikulu E, Yumuk PF, Imamoglu I, Oyan B, Cetin B, Haksoyler V, Karadurmus N, Erturk I, Evrensel T, Yilmaz H, Beypinar I, Kocer M, Pilanci KN, Seker M, Urun Y, Yildirim N, Eren T, Demirci U; Turkish Oncology Group. Esin E, et al. Among authors: karaagac m. Cancer Chemother Pharmacol. 2019 Jan;83(1):131-143. doi: 10.1007/s00280-018-3712-7. Epub 2018 Oct 30. Cancer Chemother Pharmacol. 2019. PMID: 30377778

10

Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy: a multicenter, prospective, and observational study.

Araz M, Karaagac M, Korkmaz L, Koral L, Inci F, Beypinar I, Uysal M, Artac M. Araz M, et al. Among authors: karaagac m. Cancer Chemother Pharmacol. 2019 Jun;83(6):1091-1097. doi: 10.1007/s00280-019-03831-4. Epub 2019 Apr 8. Cancer Chemother Pharmacol. 2019. PMID: 30963213

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

63 results

Search Page